St. Catherine Specialty Hospital and Israeli partners start regenerative medicine project on a global level
St. Catherine Specialty Hospital and Bonus Biogroup signed an agreement regarding strategic cooperation and partnership on the global market.
In the presence of numerous scientists from Israel and Croatia, St. Catherine Specialty Hospital and Bonus Biogroup signed an agreement regarding strategic cooperation and partnership on the global market. St. Catherine Specialty Hospital a European leader in the implementation of personalized medicine in clinical practice, and Bonus Biogroup, a leading Israeli biotechnology company specialized in developing and manufacturing cell therapy and tissue engineering products based on mesenchymal stromal cells (MSC) share common goals.
The Strategic Partnership Agreement is focused on the cooperative development of new technologies in the field of personalized (precision) medicine between St. Catherine Specialty Hospital and Bonus Biogroup, especially the development of cell therapy for degenerative diseases, COVID-19, and other inflammatory disorders, as well as the development of a new concept of laboratory tissue production, especially bone tissue.
During the press conference, Professor Dragan Primorac, M.D., Ph.D., President of the Board of Directors of St. Catherine Specialty Hospital, Dr. Shai Meretzki, CEO of Bonus Biogroup, Dr. Tomer Bronshtein, VP of Business Development of Bonus Biogroup, Professor Igor Borić, M.D., Ph.D., director of St. Catherine Specialty Hospital, and the ambassador of the State of Israel, H.E. Mr. Ilan Mor, gave a speech about the importance of personalized medicine in the future.